Aspira Offers Pfizer Vaccine

Patients age 5-11 are now eligible to receive the COVID vaccine.

Patients 12 and older are able to get vaccinated at any of our clinics provided they meet the requirements (outlined below).  Please text us at 302-517-1385 if you have questions at any time.

VACCINE CLINICS – LOCATION & TIMES:

MEDICATION INFORMATION:

Vaccine Schedule:  The routine adult schedule is one dose, followed by a second identical dose in 21 days.  The second dose does not have to be exactly at 21 days.  It can be given any time between 17 – 42 days after the first, however, it is best to get the shot as close to 21 days as possible.

Adult Vaccine Dose and Concentration (Age 12+):  Adult doses of the vaccine (1st, 2nd or 3rd, etc.) are identical in composition and volume.  They are the same medication and the dose is 0.3mL.  The concentration is 100 mcg/mL.

Pediatric Vaccine Dose and Concentration (Age 5-11):  Pediatric doses of the vaccine are 0.2mL.  The concentration is 50 mcg/mL.

We do not charge for the vaccine.  However, if you have active insurance you must present it at the time of your vaccination.

Am I Eligible?

Patients seeking their 3rd dose of vaccine must qualify under one of the criteria listed below.  Still not sure if you qualify?  Use the flowchart below to determine if you are eligible:

cdc recommendations to expand booster shot eligibility to people fully vaccinated


“MIX AND MATCH”

On Oct 22, 2021 the Delaware Division of Public Health offered guidance on the expansion of boosters to include those vaccinated with J&J or Moderna.  J&J patients who got their shot at least 2 months prior are eligible, and Moderna patients who got their final shot at least 6 months prior are eligible to receive a shot of the Pfizer vaccine if they choose.


IMMUNOCOMPROMISED

On August 12, 2021, the FDA expanded the EUA for the Pfizer-BioNTech Vaccine to authorize a 3rd dose of the same COVID-19 vaccine administered at least 28 days following the two-dose regimen of either vaccine.

This authorization is limited and only applies to eligible individuals who have undergone solid organ transplant or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

The following individuals should be considered for the 3rd dose of mRNA vaccine if they have received their first dose:

  • Organ transplant recipients taking immunosuppressive therapy
  • Recipient of stem cell transplants (CAR-T-cell or hematopoietic) within two years or taking immunosuppressive therapy
  • Active/recent cancer treatments for tumors or hematologic malignancies
  • Advanced or untreated HIV infection
  • Persons taking medications that weaken the immune system – high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)

SENIORS & HIGH-RISK GROUPS

On Sept 24, 2021 the CDC recommended and the Delaware Division of Public Health authorized the following people should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their second dose of Pfizer-BioNTech.

  • People 65 years and older and residents in long-term care settings
  • People aged 50–64 years with underlying medical conditions, which include but are not limited to: cancer, chronic heart, lung and kidney diseases, dementia, diabetes, down syndrome, HIV, overweight and obesity, pregnancy, organ transplants, and stroke.

Additionally, CDC recommends the following individuals may also receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their second dose of Pfizer-BioNTech.

  • People aged 18–49 years with underlying medical conditions (the same categories as mentioned above), based on their individual benefits and risk
  • People aged 18–64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting, including, health care workers, teachers and daycare staff, grocery workers, and those in homeless shelters or prisons, among others.

COVID Vaccine - Scientific Literature Updates

Up to date information on COVID, brought to you by Aspira.  Click on the images and links below to read the full stories.

DPH ADVISES VACCINE PROVIDERS TO OFFER PFIZER BOOSTER TO ELIGIBLE DELAWAREANS

[Sept 24, 2021]  Eligible Delawareans can now get a third (booster) shot of Pfizer’s vaccine.

 

FDA TO AUTHORIZE PFIZER VACCINE FOR 12-15 YEAR OLDS BY EARLY NEXT WEEK

FDA moving to approve vaccinations for patients age 12-15 years.

[May 3, 2021] It is reported that the Pfizer vaccine will soon be available to patients age 12-15.  Aspira is working with schools to get kids vaccinated.  Check back for news updates.

 

STATE OF DELAWARE TO VACCINATE EVERYONE 16 YEARS AND OLDER

[April 6, 2021] Starting soon, Delaware is going to begin vaccinating everyone over the age of 16 years.  Sign up now and get vaccinated at Aspira!

 

PFIZER VACCINE HIGHLY EFFECTIVE IN CHILDREN AGES 12 – 15

A 12-year-old taking part in the Pfizer vaccine trial at Cincinnati Children’s Hospital.[March 31, 2021] The Pfizer vaccine is extremely effective in adolescents 12 to 15 years old, perhaps even more so than in adults, the companies reported.  No infections were found in the study group and the participants produced strong antibody responses.

 

PFIZER VACCINE VERY EFFECTIVE IN REAL-WORLD CONDITIONS TO PREVENT INFECTIONS

A mass vaccination site at the Kentucky State Fair and Exposition Center in Louisville this month.[March 29, 2021] Pfizer’s vaccine has proven to provide powerful protection to individuals that complete the vaccination schedule.  Among those patients that were fully vaccinated, there were 0.04 infections per 1,000 person-days, meaning that among 1,000 persons there would be 0.04 infections in a day.


SECOND DOSE WINDOW: 17 – 42 DAYS AFTER FIRST

[Jan 26, 2021] Pfizer and the Delaware Division of Public Health have stated that the second dose can be given up to 42 days (6 weeks) after the first dose and the patient still benefits from a boost in immunity.  Studies have shown that this is a safe and effective strategy.

Persons should not be scheduled to receive the second dose earlier than recommended (i.e. 3 weeks for the Pfizer-BioNTech).  However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid (3).  Therefore, because of limited supply availability, it is ok to receive your second dose from Aspira anywhere between 17 and 25 days after the first for optimal administration.

If you cannot get the 2nd dose right away, do not worry.  Patients still get between 50-83% immunity from just one shot.  By comparison, the flu vaccine only offers between 45-55% immunity each year.  Simply continue to search for access and get vaccinated when you are able.

Scheduling a 2nd dose: Anyone who received their first dose from Aspira will receive an email 1-3 days before their second dose is due to let them know either (a) how to schedule their second dose at Aspira, or (b) where they might be able to find a second dose. 

We appreciate your patience in this matter.  When doses are available, scheduling will be open to the public.  Right now, public scheduling is not available.

References:
(1) https://coronavirus.delaware.gov/vaccine/vaccination-timeline/#high-medium-risk
(2) https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf
(3) https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html